当前位置： SCI文献检索 > GYNECOLOGIC ONCOLOGY期刊下所有文献 > Anti-diabetic doses of metformin decrease proliferation markers in tumors of patients with endometrial cancer.

Anti-diabetic doses of metformin decrease proliferation markers in tumors of patients with endometrial cancer.

Abstract：

BACKGROUND:Metformin has been associated with reduced cancer risk. The mechanisms underlying this cancer protective effect remain unknown. METHODS:"Window of opportunity" study of metformin in women with operable endometrial cancer (EC). Eleven newly diagnosed, untreated, non-diabetic patients with EC received metformin 500 mg tid from diagnostic biopsy to surgery. Fasting plasma insulin, insulin-like growth factor 1 (IGF-1), insulin-like growth factor binding protein 1 (IGFBP-1) and insulin-like growth factor binding protein 7 (IGFBP-7) measurements were taken before and after metformin treatment. Ki-67, pAMPK, and pS6 immunohistochemistry staining was performed on the endometrial cancer before and after metformin treatment and was compared to a control group of 10 women with EC who did not receive metformin. RESULTS:Metformin was administered for a mean of 36.6 days. None of the patients suffered side effects requiring withdrawal from the study. The study group comprised 8 patients with endometrioid EC, and 3 non-endometrioid EC, with a mean follow-up time of 57 months. Mean plasma insulin (p=0.0005), IGF-1 (p=0.001), and IGFBP-7 (p=0.0098) were significantly reduced after metformin treatment. A clear reduction in ki-67 and pS6 expression was observed by both conventional light microscope analysis and digital image analysis with a significant mean reduction in percentage of cells staining for ki-67 (9.7%, P=0.02) and pS6 (31%, P=0.03). In the non-treated control group expression was similar between the biopsy and the surgical specimens. CONCLUSIONS:This pilot trial presents biological evidence consistent with anti-proliferative effects of metformin in women with EC in the clinical setting.

journal_name

Gynecol Oncol

journal_title

Gynecologic oncology

authors

Laskov I,Drudi L,Beauchamp MC,Yasmeen A,Ferenczy A,Pollak M,Gotlieb WH

doi

10.1016/j.ygyno.2014.06.014

subject

Has Abstract

pub_date

2014-09-01 00:00:00

pages

607-14

issue

3

eissn

0090-8258

issn

1095-6859

pii

S0090-8258(14)01054-3

journal_volume

134

pub_type

杂志文章

相关文献

GYNECOLOGIC ONCOLOGY文献大全
  • Presence of oncogenic HPV DNAs in cervical carcinoma tissues and pelvic lymph nodes associating with proliferating cell nuclear antigen expression.

    abstract：:The presence of oncogenic HPV DNAs (HPV-16/18) in cervical carcinomas and their normal and metastatic pelvic lymph nodes and the expression patterns of proliferating cell nuclear antigen (PCNA) in cervical carcinomas were retrospectively studied to elucidate the possible roles of them in malignant transformation and p...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1006/gyno.1996.0066

    authors： Park JS,Rhyu KS,Kim CJ,Kim HS,Han KT,Ahn HK,Kim SJ,Namkoong SE

    更新日期：1996-03-01 00:00:00

  • Tumorigenesis of K-ras mutation in human endometrial carcinoma via upregulation of estrogen receptor.

    abstract：OBJECTIVE:To investigate the tumorigenesis of mutant [12Asp]-K-ras in endometrial carcinoma and its relationship with ER. METHODS:We constructed pcDI-[12Asp]K-ras4B by inserting full-length [12Asp]K-ras4B from human endometrial carcinoma Hec-1A cells, into pcDI vector. Cell proliferation of NIH3T3 after transfection w...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2005.10.016

    authors： Tu Z,Gui L,Wang J,Li X,Sun P,Wei L

    更新日期：2006-05-01 00:00:00

  • Bcl-X(L) is functionally non-equivalent for the regulation of growth and survival in human ovarian cancer cells.

    abstract：OBJECTIVE:To investigate the role of Bcl-X(L) on the growth and survival of human ovarian carcinoma cells. METHODS:In this study, we enforced down-regulation of Bcl-X(L) by RNA interference in ovarian carcinoma cell lines CaOV3, SKOV3ip1 and OVCAR3 cell lines expressing various levels of Bcl-X(L). We also established ...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2005.08.028

    authors： Dodier P,Piché A

    更新日期：2006-02-01 00:00:00

  • Advanced endometrial cancer detected at 7 months after childbirth.

    abstract：:It is very rare to find endometrial cancers arising within a short period following childbirth, presumably because pregnancy has a protective effect against endometrial cancer mediated by elevated secretion of progesterone. We present the case of a 30-year-old Japanese woman with stage IIIC endometrial cancer that was...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章,评审

    doi：10.1006/gyno.1996.4556

    authors： Kodama J,Yoshinouchi M,Miyagi Y,Kobashi Y,Kamimura S,Okuda H,Kudo T

    更新日期：1997-03-01 00:00:00

  • Phase II trial of intraperitoneal cisplatin with intravenous doxorubicin and cyclophosphamide in previously untreated patients with advanced ovarian cancer-long-term follow-up.

    abstract：:Forty-three patients with ovarian cancer were entered on this trial and treated with intravenous (iv) cyclophosphamide (C) and doxorubicin (A), and intraperitoneal (ip) cisplatin (DDP), every 21 days for eight cycles. Following iv hydration, the cisplatin was administered through an intraperitoneal catheter in 2 L of ...

    journal_title：Gynecologic oncology

    pub_type： 临床试验,杂志文章

    doi：10.1006/gyno.1999.5613

    authors： Morgan RJ Jr,Braly P,Cecchi G,Leong L,Shibata S,Margolin K,Somlo G,McNamara M,Longmate J,Schinke S,Raschko J,Nagasawa S,Kogut N,Parker P,Stein A,Cho J,Smith E,Coluzzi P,Najera L,Johnson D,Womack E,Doroshow JH

    更新日期：1999-12-01 00:00:00

  • The prognostic value of residual disease after neoadjuvant chemotherapy in advanced ovarian cancer; A systematic review.

    abstract：INTRODUCTION:The ability to minimize residual disease during primary cytoreductive surgery is the strongest predictor for improved overall survival in advanced ovarian cancer. But while the probability to achieve a macroscopic complete resection increases if surgery is preceded by neoadjuvant chemotherapy (NACT), survi...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2019.02.019

    authors： Timmermans M,van der Hel O,Sonke GS,Van de Vijver KK,van der Aa MA,Kruitwagen RF

    更新日期：2019-05-01 00:00:00

  • Continuous epidural infusion in gynecologic oncology patients undergoing exploratory laparotomy: The new standard for decreased postoperative pain and opioid use.

    abstract：OBJECTIVE:To compare the incidence of postoperative complications and opioid pain medication usage in gynecologic oncology patients who did and did not receive an epidural prior to undergoing exploratory laparotomy. METHODS:Retrospective cohort study of all patients undergoing exploratory laparotomy with the gynecolog...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2019.02.017

    authors： Huepenbecker SP,Cusworth SE,Kuroki LM,Lu P,Samen CDK,Woolfolk C,Deterding R,Wan L,Helsten DL,Bottros M,Mutch DG,Powell MA,Massad LS,Thaker PH

    更新日期：2019-05-01 00:00:00

  • Therapeutic potential of the new TRIB3-mediated cell autophagy anticancer drug ABTL0812 in endometrial cancer.

    abstract：OBJECTIVES:The PI3K/AKT/mTOR pathway is frequently overactivated in endometrial cancer (EC). We assessed the efficacy of ABTL0812, a novel first-in-class molecule presenting a unique mechanism of action inhibiting this pathway. METHODS:We investigated the effects of ABTL0812 on proliferation, cell death and modulation...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2019.03.002

    authors： Felip I,Moiola CP,Megino-Luque C,Lopez-Gil C,Cabrera S,Solé-Sánchez S,Muñoz-Guardiola P,Megias-Roda E,Pérez-Montoyo H,Alfon J,Yeste-Velasco M,Santacana M,Dolcet X,Reques A,Oaknin A,Rodríguez-Freixinos V,Lizcano JM,Domèn

    更新日期：2019-05-01 00:00:00

  • Immunotherapy and radiation combinatorial trials in gynecologic cancer: A potential synergy?

    abstract：:Immunotherapy (IO) is an important new pillar in the treatment of solid tumors, and the integration of IO agents with chemotherapy, targeted therapy, surgery and radiation has yet to be defined. As preclinical and clinical studies have described synergistic activity with the combination of radiation and immunotherapy,...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章,评审

    doi：10.1016/j.ygyno.2019.03.255

    authors： Lee L,Matulonis U

    更新日期：2019-07-01 00:00:00

  • Malignant ovarian tumor composed of endometrioid adenocarcinoma, clear cell adenocarcinoma, squamous cell carcinoma, yolk sac tumor and immature teratoma with prominent neuroectodermal and rhabdomyosarcomatous differentiation: a case study.

    abstract：BACKGROUND:Cases of malignant ovarian tumor composed of müllerian-type epithelial tumor and malignant germ cell tumor are extremely rare. CASE:We herein report the case of a 34-year-old woman with an ovarian tumor which was composed of endometrioid adenocarcinoma (EAC), clear cell adenocarcinoma (CCC), squamous cell c...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2007.02.003

    authors： Ohishi Y,Kaku T,Kaneki E,Wake N,Tsuneyoshi M

    更新日期：2007-05-01 00:00:00

  • Characterization of CSOC 882, a novel immortalized ovarian cancer cell line expressing EGFR, HER2, and activated AKT.

    abstract：OBJECTIVE:Only a small number of comprehensively characterized immortalized ovarian cancer cell lines are available for laboratory studies on ovarian cancer. We describe a new ovarian cancer cell line that arose from primary culture of a stage IC, grade III ovarian carcinoma, designated CSOC 882. METHODS:We characteri...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2006.07.023

    authors： Scoles DR,Pavelka J,Cass I,Tran H,Baldwin RL,Armstrong K,Karlan BY

    更新日期：2007-01-01 00:00:00

  • Nongestational pure ovarian choriocarcinoma with contralateral teratoma.

    abstract：BACKGROUND:Nongestational pure ovarian choriocarcinoma is a rare malignancy with only 29 cases described to date. CASE:We describe a case associated with mature cystic teratoma of the contralateral ovary. Details of all 30 cases including clinical features, associations, surgicopathological findings, operative procedu...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章,评审

    doi：10.1006/gyno.2000.6043

    authors： Goswami D,Sharma K,Zutshi V,Tempe A,Nigam S

    更新日期：2001-02-01 00:00:00

  • Optimal surgical debulking in uterine papillary serous carcinoma affects survival.

    abstract：OBJECTIVE:UPSC is similar to papillary serous ovarian carcinoma in its histology and pattern of spread. The survival advantage with optimal debulking for ovarian cancer has been demonstrated. We examined our experience with UPSC. METHODS:Seventy-eight UPSC patients were seen between 1995 and 2008 at Rush University Me...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2010.11.048

    authors： Patsavas K,Woessner J,Gielda B,Rotmensch J,Yordan E,Bitterman P,Guirguis A

    更新日期：2011-06-01 00:00:00

  • Mucinous borderline ovarian tumor versus invasive well-differentiated mucinous ovarian cancer: Difference in characteristics and outcomes.

    abstract：OBJECTIVE:Mucinous borderline ovarian tumor (mucinous-BOT) and invasive well-differentiated mucinous ovarian cancer (mucinous-OC) are often histopathologically misclassified. The objective of this study was to examine differences in clinico-pathological characteristics and outcomes of these two entities. METHODS:This ...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2019.02.003

    authors： Matsuo K,Machida H,Mandelbaum RS,Grubbs BH,Roman LD,Sood AK,Gershenson DM

    更新日期：2019-05-01 00:00:00

  • Ascites, pleural effusion, and CA 125 elevation in an SLE patient, either a Tjalma syndrome or, due to the migrated Filshie clips, a pseudo-Meigs syndrome.

    abstract：BACKGROUND:The combination ascites, pleural effusion, and elevated CA 125 are usually associated with a malignancy. CASE:A 38-year-old SLE patient consulted her physician for shortness of breath. On clinical examination, she had a tender abdomen and reduced breathing sounds. X-ray and computed tomography of the chest ...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2004.12.022

    authors： Tjalma WA

    更新日期：2005-04-01 00:00:00

  • The prognostic and therapeutic implications of cytologic atypia in patients with endometrial hyperplasia.

    abstract：:From 1970 to 1992, 136 patients with a histologic diagnosis of endometrial hyperplasia underwent total abdominal hysterectomy at the University of Kentucky Medical Center. Slides of the curettage or biopsy specimens were reviewed and classified according to the International Society of Gynecologic Pathologists System ...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1006/gyno.1994.1249

    authors： Hunter JE,Tritz DE,Howell MG,DePriest PD,Gallion HH,Andrews SJ,Buckley SB,Kryscio RJ,van Nagell JR Jr

    更新日期：1994-10-01 00:00:00

  • Neuroendocrine carcinoma of the uterine cervix: the role of multimodality therapy in early-stage disease.

    abstract：BACKGROUND:Neuroendocrine carcinomas (NECs) of the cervix comprise only 2% of all cervical cancers. Prospective data is limited and treatment guidelines rely on retrospective reviews and literature from lung NEC. The objective of this study was to report our experience in the management of this rare disease. METHODS:T...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2013.01.014

    authors： McCann GA,Boutsicaris CE,Preston MM,Backes FJ,Eisenhauer EL,Fowler JM,Cohn DE,Copeland LJ,Salani R,O'Malley DM

    更新日期：2013-04-01 00:00:00

  • Concurrent chemoradiation in advanced cervical cancer.

    abstract：:The pelvis is the predominant site of failure following radical radiotherapy (RT) for locally advanced cervical cancer. We report the results of phase I-II studies on 200 patients with bulky (greater than or equal to 5 cm) carcinoma of the cervix. Patients were treated between 1981 and 1988 on sequential protocols of ...

    journal_title：Gynecologic oncology

    pub_type： 临床试验,杂志文章,评审

    doi：10.1016/0090-8258(90)90089-4

    authors： Thomas G,Dembo A,Fyles A,Gadalla T,Beale F,Bean H,Pringle J,Rawlings G,Bush R,Black B

    更新日期：1990-09-01 00:00:00

  • Beyond prophylaxis: Extended risk of venous thromboembolism following primary debulking surgery for ovarian cancer.

    abstract：OBJECTIVE:To determine the incidence and risk factors for venous thromboembolism (VTE) within six months after primary debulking surgery (PDS) for epithelial ovarian cancer (EOC). METHODS:In a historical cohort, we estimated the cumulative incidence of clinically diagnosed VTE within 6 months among consecutive women w...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2018.11.021

    authors： Wagner BE,Langstraat CL,McGree ME,Weaver AL,Sarangi S,Mokri B,Dowdy SC,Cliby WA,Kumar A,Bakkum-Gamez JN

    更新日期：2019-02-01 00:00:00

  • The prescription or proscription of exercise in endometrial cancer care.

    abstract：OBJECTIVE:To determine the proportion of endometrial cancer patients who can be safely prescribed community/home based unsupervised exercise. A better understanding of the physical dysfunction secondary to comorbidities among endometrial cancer patients would assist clinicians in delineating which patients to send to m...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2015.08.007

    authors： Zhang X,Haggerty AF,Brown JC,Giuntoli R 2nd,Lin L,Simpkins F,Dean LT,Ko E,Morgan MA,Schmitz KH

    更新日期：2015-10-01 00:00:00

  • A phase II trial of dolastatin-10 in recurrent platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study.

    abstract：OBJECTIVE:To estimate the antitumor efficacy of dolastatin-10 in patients with measurable recurrences of platinum-sensitive ovarian carcinoma and to determine the nature and degree of toxicity of dolastatin-10 in these patients. METHODS:Patients received dolastatin-10 400 microg/m(2) intravenously every 3 weeks and tu...

    journal_title：Gynecologic oncology

    pub_type： 临床试验,杂志文章,多中心研究

    doi：10.1016/s0090-8258(03)00007-6

    authors： Hoffman MA,Blessing JA,Lentz SS,Gynecologic Oncology Group Study.

    更新日期：2003-04-01 00:00:00

  • Ovarian intraepithelial neoplasia demonstrated in patients with stage I ovarian carcinoma.

    abstract：:Retrospective review of sections of ovary from 50 patients with stage I, grade 1-3, epithelial ovarian carcinoma was performed to assess presence of cellular and nuclear atypia in noncancerous tissue adjacent to the primary tumor; ovarian tissue from 50 patients undergoing incidental oophorectomy was reviewed as well....

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/0090-8258(90)90075-v

    authors： Plaxe SC,Deligdisch L,Dottino PR,Cohen CJ

    更新日期：1990-09-01 00:00:00

  • Are self-collected samples comparable to physician-collected cervical specimens for human papillomavirus DNA testing? A systematic review and meta-analysis.

    abstract：OBJECTIVE:To compare the detection rate of genital human papillomavirus (HPV) infection in self- and physician-obtained samples. DESIGN:Systematic review and meta-analysis. DATA SOURCES:Studies published between 1966 and November 2005 identified through Medline and Embase that compared both sampling methods. MAIN OU...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章,meta分析,评审

    doi：10.1016/j.ygyno.2007.01.023

    authors： Petignat P,Faltin DL,Bruchim I,Tramèr MR,Franco EL,Coutlée F

    更新日期：2007-05-01 00:00:00

  • Costs of treatment and outcomes associated with second-line therapy and greater for relapsed ovarian cancer.

    abstract：OBJECTIVES:Most women with epithelial ovarian cancer (EOC) will develop disease progression or recurrence with resistance to platinum therapy. We report overall costs and treatment outcomes associated with topotecan or gemcitabine administration in platinum- and paclitaxel-resistant EOC patients. METHODS:Patients who ...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2004.01.014

    authors： Prasad M,Ben-Porat L,Hoppe B,Aghajanian C,Sabbatini P,Chi DS,Hensley ML

    更新日期：2004-04-01 00:00:00

  • Salvage therapy in ovarian cancer: is there a role for intraperitoneal drug delivery?

    abstract：:Phase 2 trials employing several antineoplastic agents have demonstrated that surgically documented responses, including complete responses, can result when patients with ovarian cancer are treated by the intraperitoneal route in the salvage setting following initial systemic chemotherapy. Activity is essentially limi...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章,评审

    doi：10.1006/gyno.1993.1251

    authors： Markman M

    更新日期：1993-10-01 00:00:00

  • CO2 laser therapy for cervical intraepithelial neoplasia.

    abstract：:One hundred and fifty-six patients with cervical intraepithelial neoplasia (CIN) were treated with CO2 laser and followed for 2 1/2 to 6 years. There were 19 recurrences, of which 14 occurred in patients treated with a power density of less than 1000 W/cm2 to a depth of 6 mm. All of the recurrences were subjected to a...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/0090-8258(85)90006-x

    authors： Caglar H,Ayhan A,Hreshchyshyn MM

    更新日期：1985-09-01 00:00:00

  • Role of hysterectomy in management of gestational trophoblastic disease.

    abstract：OBJECTIVE:To evaluate incidence, indications, and outcome of hysterectomy in women presenting with gestational trophoblastic disease. METHODS:A prospective observational study using a standardized protocol for registration, assessment, and treatment of gestational trophoblastic disease. A total of 5976 consecutive new...

    journal_title：Gynecologic oncology

    pub_type： 临床试验,杂志文章

    doi：10.1006/gyno.2002.6814

    authors： Pisal N,North C,Tidy J,Hancock B

    更新日期：2002-11-01 00:00:00

  • Failure of hexamethylmelamine as salvage therapy in ovarian epithelial adenocarcinoma resistant to combination chemotherapy.

    abstract：:Favorable responses to hexamethylmelamine (HMM) have been documented in untreated as well as in alkylating agent-resistant ovarian epithelial adenocarcinoma (OvCa). Platinum-based combination therapy for OvCa has been used since 1976. Eighteen patients with OvCa were treated with HMM as salvage therapy between Februar...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/0090-8258(84)90076-3

    authors： Stehman FB,Ehrlich CE,Callangan MF

    更新日期：1984-02-01 00:00:00

  • Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer.

    abstract：OBJECTIVE:The AGO-OVAR16 study was designed to test the efficacy, safety, and tolerability of pazopanib maintenance after first-line chemotherapy in patients with newly diagnosed advanced ovarian cancer (AOC). METHODS:Nine hundred and forty patients with histologically confirmed AOC, International Federation of Gyneco...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1016/j.ygyno.2019.08.024

    authors： Vergote I,du Bois A,Floquet A,Rau J,Kim JW,Del Campo JM,Friedlander M,Pignata S,Fujiwara K,Colombo N,Mirza MR,Monk BJ,Tsibulak I,Calvert PM,Herzog TJ,Hanker LC,Meunier J,Lee JY,Bologna A,Carrasco-Alfonso MJ,Harter

    更新日期：2019-11-01 00:00:00

  • Age-specific trends in black-white disparities in cervical cancer incidence in the United States: 1975-2009.

    abstract：BACKGROUND:Although overall cervical cancer incidence rates have decreased in both black and white women in the U.S. since the mid 1950s due to widespread screening, rates continue to be higher among blacks than among whites. However, whether this pattern differs by age is unknown. METHODS:Cervical cancer cases (1975-...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2012.08.021

    authors： Simard EP,Naishadham D,Saslow D,Jemal A

    更新日期：2012-12-01 00:00:00